Home › Trial NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
- Trial IDNCT02851589
- StatusUnknown
- PhasePhase 1/2
- Study typeInterventional
- SponsorPersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Enrollment10
- Start date2016-07
- ConditionsAcute Lymphocytic Leukemia · Chronic Lymphocytic Leukemia · Follicular Lymphoma · Mantle Cell Lymphoma · B-cell Prolymphocytic Leukemia · Diffuse Large Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.